论文部分内容阅读
目的探讨贝伐单抗联合多西他赛治疗晚期宫颈癌的临床疗效及安全性。方法收集2011年4月—2016年4月于西安医学院第二附属医院进行治疗的晚期宫颈癌患者75例作为研究对象进行回顾性分析,按照治疗方法的不同将其分为观察组43例和对照组32例。对照组患者仅使用多西他赛治疗,观察组在此基础上加用贝伐单抗。对两组患者临床疗效、不良反应、生活质量以及药物经济学进行考察与比较。结果观察组总有效率和临床控制率均显著高于对照组,差异有统计学意义(P<0.05)。两组患者在血液系统、消化系统及其他毒副反应发生率方面均无显著差异。观察组生活质量改善总有效率为83.72%,对照组为62.50%,观察组显著高于对照组,差异有统计学意义(P<0.05)。观察组平均治疗费用为(8.3±1.0)万元,对照组为(1.8±0.6)万元,观察组显著高于对照组,差异有统计学意义(P<0.05)。结论贝伐单抗联合多西他赛治疗晚期宫颈癌临床疗效优于多西紫杉醇单药,但费用高昂,需结合患者自身情况制定治疗方案。
Objective To investigate the clinical efficacy and safety of bevacizumab plus docetaxel in the treatment of advanced cervical cancer. Methods Seventy-five patients with advanced cervical cancer who were treated in the Second Affiliated Hospital of Xi’an Medical University from April 2011 to April 2016 were retrospectively analyzed. According to the different treatment methods, they were divided into observation group (43 cases) and control group Control group of 32 cases. Patients in the control group received only docetaxel, and the observation group received bevacizumab on the basis of this. The clinical efficacy, adverse reactions, quality of life and pharmacoeconomics in both groups were investigated and compared. Results The total effective rate and clinical control rate in the observation group were significantly higher than those in the control group, the difference was statistically significant (P <0.05). There was no significant difference between the two groups in the incidence of hematological, digestive and other toxicities. The total effective rate of observation group was 83.72%, while that of control group was 62.50%. The observation group was significantly higher than that of control group (P <0.05). The average cost of treatment in the observation group was (8.3 ± 1.0) million yuan and that in the control group was (1.8 ± 0.6) million yuan. The observation group was significantly higher than that of the control group (P <0.05). Conclusion Bevacizumab combined with docetaxel in the treatment of advanced cervical cancer clinical efficacy is better than docetaxel single drug, but the high cost, the need to develop their own treatment programs.